Abera Bioscience AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Net Income	-10.45	-1.1	-16.72	-19.38	-9.17	Upgrade
Depreciation & Amortization	0.19	0.06	-	-	-	Upgrade
Other Operating Activities	-0	0	-	0	-	Upgrade
Change in Accounts Receivable	2.72	-0.35	-1.89	-0.86	-0.31	Upgrade
Change in Other Net Operating Assets	4.29	1.19	0.9	0.54	-0.21	Upgrade
Operating Cash Flow	-3.26	-0.2	-17.71	-19.69	-9.68	Upgrade
Capital Expenditures	-0.43	-1.13	-	-	-	Upgrade
Investing Cash Flow	-0.43	-1.13	-	-	-	Upgrade
Issuance of Common Stock	21.5	4	5.6	24.05	23.08	Upgrade
Other Financing Activities	-0.42	0.1	-0	-0.88	-2.35	Upgrade
Financing Cash Flow	21.08	4.1	5.6	23.17	20.73	Upgrade
Net Cash Flow	17.4	2.77	-12.11	3.48	11.05	Upgrade
Free Cash Flow	-3.68	-1.33	-17.71	-19.69	-9.68	Upgrade
Free Cash Flow Margin	-30.99%	-9.09%	-701.70%	-1101.46%	-821.76%	Upgrade
Free Cash Flow Per Share	-0.22	-0.09	-1.33	-1.69	-0.95	Upgrade
Cash Interest Paid	-	0	-	-	0	Upgrade
Levered Free Cash Flow	0.16	-1.07	-11.57	-13.35	-6.36	Upgrade
Unlevered Free Cash Flow	0.16	-1.07	-11.57	-13.35	-6.36	Upgrade
Change in Working Capital	7.01	0.84	-0.99	-0.31	-0.51	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.